MW 001

Drug Profile

MW 001

Alternative Names: MW-001

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedWell Laboratories
  • Class Anti-inflammatories
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Atopic dermatitis; Eczema; Multiple sclerosis; Non-alcoholic fatty liver disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis

Highest Development Phases

  • Phase I/II Atopic dermatitis; Eczema; Psoriasis
  • Preclinical Multiple sclerosis; Non-alcoholic fatty liver disease; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 05 Aug 2016 MW 001 is available for licensing as of 05 Aug 2016. http://www.medwell-laboratories.com/
  • 05 Aug 2016 Phase-I/II clinical trials in Atopic dermatitis (In children, In infants, In neonates, In adolescents) in Israel (Topical)
  • 05 Aug 2016 Phase-I/II clinical trials in Eczema (In adults) in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top